STATUS: Recruiting

SPONSOR: Merck Sharp & Dohme LLC
LEAD GROUP: BGOG
ENGOT Model: C
TITLE: A Phase 3, Randomized, Double-Blind Study of Pembrolizumab versus Placebo in Combination With Adjuvant Chemotherapy With or Without Radiotherapy for the Treatment of Newly Diagnosed High-Risk Endometrial Cancer After Surgery With Curative Intent (GOG-3053)
ClinicalTrials.gov ID:  NCT04634877
MaNGO sites (click to see the list)

STATUS: Recruiting

SPONSOR: Incyte Corporation
LEAD GROUP: NOGGO
ENGOT Model: C
TITLE: An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy
ClinicalTrials.gov ID: NCT04463771
MaNGO sites (click to see the list)

STATUS: Planned

SPONSOR: GINECO
LEAD GROUP: GINECO
ENGOT Model: A
TITLE: Randomized phase III trial in MMR deficient endometrial cancer patients comparing chemotherapy alone versus dostarlimab in first line advanced/metastatic setting.
ClinicalTrials.gov ID: NCT05201547
MaNGO sites (click to see the list)

STATUS: Planned

SPONSOR: Leiden University Medical Center
LEAD GROUP: DGOG
ENGOT Model: A
TITLE: A phase II study of tailored adjuvant therapy in Pole-mutated and p53-wildtype/NSMP early stage endometrial cancer (RAINBO BLUE & TAPER)
ClinicalTrials.gov ID: NCT05255653    
MaNGO sites (click to see the list)     

STATUS: Planned

SPONSOR: Karyopharm Therapeutics Inc.
LEAD GROUP: BGOG
ENGOT Model: C
TITLE: A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma
ClinicalTrials.gov ID: NCT05611931
MaNGO sites (click to see the list)

STATUS: Planned

SPONSOR: Kartos Therapeutics, Inc.
LEAD GROUP: AGO-Austria
ENGOT Model: C
TITLE: A Two-part, Randomized Phase 2/3 Study of Navtemadlin in Subjects with TP53 WT Advanced or Recurrent Endometrial Cancer Who Responded after Chemotherapy
ClinicalTrials.gov ID: NCT05797831
MaNGO sites (click to see the list)

STATUS: Planned

SPONSOR: AGO Study Group
LEAD GROUP: AGO Study Group
ENGOT Model: A
TITLE: Evaluation of preoperative clinical and translation selection criteria for cytoreductive surgery in endometrial cancer . A retrospective multicenter trial with an accompanying translational Project. Surgical Treatment in Advanced and Recurrent Endometrial CAncer Management
ClinicalTrials.gov ID: to be defined
MaNGO sites (click to see the list)    

STATUS: Planned

SPONSOR: Merck Sharp & Dohme LLC
LEAD GROUP: MITO
ENGOT Model: C
TITLE: A Phase 3, Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician’s Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-Based Chemotherapy and Immunotherapy
ClinicalTrials.gov ID:  to be defined
MaNGO sites (click to see the list)  

STATUS: Planned
SPONSOR: AstraZeneca

LEAD GROUP: NSGO
ENGOT Model: C
TITLE: An Open label, Randomized, Multicenter, Controlled, Phase III Study of First-Line Trastuzumab Deruxtecan (T-DXd) Monotherapy versus Carboplatin and Paclitaxel with or without Pembrolizumab in Patients with HER2-expressing (IHC 3+/IHC2+) Mismatch Repair Proficient (pMMR) Primary Advanced or Recurrent Endometrial Cancer
ClinicalTrials.gov ID: to be defined
MaNGO sites (click to see the list)    

STATUS: Planned
SPONSOR: BioNTech SE

LEAD GROUP: NSGO
ENGOT Model: C
TITLE: A Phase III, randomized, multi-site, open-label trial of BNT323/DB-1303 versus investigator’s choice of chemotherapy in previously treated patients with HER2-expressing recurrent or metastatic endometrial cancer

ClinicalTrials.gov ID: to be defined

MaNGO sites(click to see the list)